SignatureFD
RXRX icon

SignatureFD’s Recursion Pharmaceuticals RXRX Stock Holding History

SignatureFD’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$37.9K Sell
9,180
-702
-7% -$2.38K ﹤0.01% 2121
2026
Q2 		$36.3K Sell
9,882
-224
-2% -$746 ﹤0.01% 2052
2026
Q1 		$31K Buy
10,106
+1,456
+17% +$5.63K ﹤0.01% 1992
2025
Q4 		$35.4K Sell
8,650
-220
-2% -$1.09K ﹤0.01% 1847
2025
Q3 		$43.3K Buy
8,870
+322
+4% +$1.69K ﹤0.01% 1711
2025
Q2 		$43.3K Sell
8,548
-2,942
-26% -$14.5K ﹤0.01% 1662
2025
Q1 		$60.8K Sell
11,490
-279
-2% -$2.03K ﹤0.01% 1462
2024
Q4 		$79.6K Buy
11,769
+3,651
+45% +$24.5K ﹤0.01% 1346
2024
Q3 		$53.5K Buy
8,118
+472
+6% +$3.38K ﹤0.01% 1538
2024
Q2 		$57.3K Buy
7,646
+32
+0.4% +$279 ﹤0.01% 1443
2024
Q1 		$75.9K Buy
7,614
+3,200
+72% +$35.6K ﹤0.01% 1338
2023
Q4 		$43.5K Buy
4,414
+94
+2% +$670 ﹤0.01% 1536
2023
Q3 		$33K Sell
4,320
-22
-0.5% -$219 ﹤0.01% 1606
2023
Q2 		$32.4K Buy
4,342
+92
+2% +$644 ﹤0.01% 1660
2023
Q1 		$28.3K Hold
4,250
– – ﹤0.01% 1680
2022
Q4 		$32.8K Hold
4,250
– – ﹤0.01% 1566
2022
Q3 		$45K Hold
4,250
– – ﹤0.01% 1324
2022
Q2 		$35K Hold
4,250
– – ﹤0.01% 1492
2022
Q1 		$30K Hold
4,250
– – ﹤0.01% 1634
2021
Q4 		$73K Hold
4,250
– – ﹤0.01% 1165
2021
Q3 		$98K Buy
+4,250
New +$120K ﹤0.01% 984

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

SignatureFD's RXRX Position: Q3 2026 in Review

SignatureFD reduced its Recursion Pharmaceuticals (RXRX) stake by 7.1% in Q3 2026, selling an estimated $2.38K and leaving 9,180 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

SignatureFD first reported a position in RXRX in Q3 2021 and has held it in 21 quarters since. The position peaked at $98K in Q3 2021. 174 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • SignatureFD held 9,180 shares of Recursion Pharmaceuticals worth $37.9K as of Q3 2026.
  • SignatureFD sold 702 Recursion Pharmaceuticals shares in Q3 2026, an estimated $2.38K.
  • Recursion Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2121 holding.
  • SignatureFD first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
  • SignatureFD's Recursion Pharmaceuticals position peaked at $98K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.